MARKET

TVRD

TVRD

Tvardi Therapeutics Inc
NASDAQ
3.940
-0.010
-0.25%
Opening 12:44 12/18 EST
OPEN
4.000
PREV CLOSE
3.950
HIGH
4.055
LOW
3.910
VOLUME
35.56K
TURNOVER
--
52 WEEK HIGH
43.65
52 WEEK LOW
3.740
MARKET CAP
36.96M
P/E (TTM)
-0.4716
1D
5D
1M
3M
1Y
5Y
1D
Tvardi Therapeutics Approves New Severance and Retention Compensation Plan for Executives
Reuters · 31m ago
Weekly Report: what happened at TVRD last week (1208-1212)?
Weekly Report · 3d ago
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
Barchart · 12/11 09:15
Weekly Report: what happened at TVRD last week (1201-1205)?
Weekly Report · 12/08 10:31
Weekly Report: what happened at TVRD last week (1124-1128)?
Weekly Report · 12/01 10:26
Weekly Report: what happened at TVRD last week (1117-1121)?
Weekly Report · 11/24 10:31
Tvardi Therapeutics: Buy Rating Reaffirmed Amid Upcoming Catalysts and Risk-Reward Scenario
TipRanks · 11/21 17:45
Tvardi Therapeutics Advances STAT3 Inhibitor Clinical Trials
TipRanks · 11/19 11:58
More
About TVRD
Tvardi Therapeutics, Inc., formerly Cara Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting (STAT3) to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Webull offers Tvardi Therapeutics Inc stock information, including NASDAQ: TVRD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TVRD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TVRD stock methods without spending real money on the virtual paper trading platform.